A CDC snapshot (as of May 23, 2026) shows many more children reported getting a seasonal flu vaccine than a 2025–26 COVID-19 vaccine. Here’s a calm, step-by-step catch-up plan and how families can use the VFC program if cost is a barrier.
On June 12, 2026, the FDA approved an ODACTRA (house dust mite) sublingual immunotherapy label update adding “dizziness” and “rash” to postmarketing adverse-reaction wording. Here’s what that means for allergy symptom monitoring, who should not use ODACTRA, and when to stop and get urgent help.
FDA’s VRBPAC reviewed investigational Moderna’s mRNA flu vaccine candidate (mFlusiva/mRNA-1010) for adults 50+. The Phase 3 signal showed a relative efficacy benefit versus a standard-dose comparator, but short-term reactions were more common than in the comparator. Key uncertainties—like limited data in the frail/high-risk older adults and limited duration-of-protection evidence—remain. CDC guidance is still to get an approved flu vaccine now rather than waiting.
CMS issued an interim final rule for Medicaid “community engagement” (80 hours/month) that states generally must start by Jan. 1, 2027. Here’s who is subject, what can count toward the hours, which exemptions—including medical frailty—may apply, and what to do if your state can’t verify compliance.
FDA posted a May 26, 2026 voluntary medical device correction for certain Omnipod 5, Omnipod DASH, and Omnipod Eros (insulin management system) pod lots due to a manufacturing issue that could cause insulin under-delivery. Here’s how to check your pod lot and when DKA warning signs mean you need emergency care.
EPA updated its home asthma-trigger guidance on July 6, 2026. Use this practical room-by-room routine to reduce exposure to wood smoke, dust mites, mold/moisture, pets, and irritant chemicals—plus clear danger signs for when to get emergency help.
CMS says enforcement of updated hospital price-transparency requirements starts April 1, 2026. For rural patients, CMS’s enforcement-activity dataset can help you see where compliance reviews happened and what CMS did—but it won’t tell you your exact out-of-pocket bill.
Starting July 1, 2026, eligible Medicare Part D beneficiaries can access certain GLP-1 weight-loss medicines through the Medicare GLP-1 Bridge at a predictable $50/month copay, through December 31, 2027. Eligibility depends on age, BMI/health conditions, and whether someone already gets a GLP-1 through their Part D plan.
FDA warns that the TRUE METRIX “E-5” message can mean either a very high blood sugar event (over 600 mg/dL) or a test-strip error. Don’t guess—switch to an alternative glucose-testing method if possible, keep testing until you have an alternative, and contact your clinician right away if E-5 shows up with symptoms of low or high blood sugar.
FDA has advised manufacturers to use an updated, monovalent 2026–2027 COVID-19 vaccine formula targeting a JN.1-lineage variant called XFG for use in fall 2026. Here’s what that “strain/formula” decision does—and what stays the same—plus practical steps for families using CDC’s risk-based vaccine guidance.
A good home blood pressure reading depends on using a validated upper-arm cuff, the right cuff size, correct positioning, and repeat measurements. Here’s how—and when a very high reading needs urgent help.
CMS says enforcement of updated hospital price transparency requirements begins April 1, 2026. In its June 26, 2026 FAQs, CMS also clarifies how hospitals should encode “allowed amount” percentile elements in the machine-readable file and how to ensure automated download access—while reporting shows CMS warning activity continuing at scale.
FDA says BD is recalling specific lots of ChloraPrep™ Clear applicators due to a potential for Aspergillus contamination. If you recently had surgery or an IV/catheter—especially if you’re immunocompromised—here’s what to ask and what symptoms to watch for.
The FDA updated its safety communication on July 2, 2026, confirming a Class I recall for certain Insulet Omnipod pods. If you use Omnipod, check the pod lot, stop using pods from affected lots, change your pod immediately if yours may be affected, monitor glucose closely, and follow your ketone plan—especially if high blood sugar doesn’t improve.
CDC’s “Activity Levels” and “Illness Severity” indicators are designed to show community trends in respiratory virus spread and hospital burden. This guide explains what the levels can—and can’t—tell you, how wastewater fits in, and what practical “protect more” steps families and schools can take without panic.
CMS updated its local Medicare coverage policy for implantable CGMs on June 25, 2026. Here’s what eligibility typically depends on, what to document for your visit, and key safety/practical limits.
A new Cell study suggests that, for some people with Long COVID, the immune system may produce autoantibodies that recognize nervous-system targets—linked to specific neurological symptom patterns. But there’s still no routine blood test or proven, antibody-targeted treatment for everyday care.
If you ate requesón or soft ricotta-style cheese tied to a June 2026 Listeria investigation, check whether it’s part of the Clover Hill Dairy recall and monitor for symptoms. Symptoms often begin in about 2 weeks, but can start as early as the same day or as late as 10 weeks—so timing matters, especially for pregnant people, older adults, and immunocompromised people.
A June 17, 2026 Federal Register final order codified a Class II (“special controls”) pathway for certain AI/ML radiology quantitative imaging software that uses an FDA-authorized Predetermined Change Control Plan (PCCP). In plain terms: when AI software updates are planned and bounded, FDA expects evidence, risk controls, and labeling—so clinicians can better understand when performance may change and how to verify results.
After rodent urine, droppings, or nesting material exposure, hantavirus illness can start like flu or stomach upset and then worsen. Here’s when to seek testing—and when to treat breathing trouble as an emergency.
A June 18, 2026 JAMA Network article reports that people whose diets have a higher share of calories from ultraprocessed foods (UPFs) show worse cardiometabolic markers and higher long-term all-cause mortality in an NHANES-based analysis. Here’s how to interpret the findings correctly—and how to reduce UPFs realistically this week without treating all processed foods as the same.
FDA’s July 1, 2026 expanded Casgevy (exa-cel) use for children as young as age 2 with severe sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOCs). “Approved” doesn’t automatically mean every 3-year-old can receive it right away—eligibility details and specialized-center capacity for intensive monitoring matter.
End of content
End of content
